Skip to main content
Explore URMC
menu

Frank C. Passero, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

As a physician I aim to provide patients with an understanding of their medical condition and guidance as they navigate complex medical decisions. I consider honesty, compassion and my medical knowledge as foundational principles upon which I seek to build a trusting patient-physician relationship. Getting to know my patients, their unique circumstances and goals is a key aspect of my practice, in order to provide patients with a personalized plan of care.

I obtained my medical degree from Jefferson Medical College in Philadelphia, Pennsylvania and went on to complete internship, residency, and a chief medical residency in Internal Medicine at Scripps Mercy Hospital in San Diego. I pursued my Hematology and Oncology fellowship training at Tufts Medical Center in Boston, Massachusetts where I carried out laboratory research studying the effects of proteasome and HDAC inhibitors in lymphoma.

I have a special interest in plasma cell disorders including myeloma and amyloidosis, and would like to provide patients with the opportunity to participate in well-designed clinical trials for these and other related diseases.

Credentials

Education

2010
MD | Thomas Jefferson University Hospital

Post-doctoral Training & Residency

07/01/2014 - 06/30/2017
Fellowship in Hematology & Oncology at Tufts Medical Center

07/01/2011 - 06/30/2014
Residency in Internal Medicine at Mercy Hospital & Medical Center-San Diego (GME)

06/24/2010 - 06/23/2011
Internship in Internal Medicine at Mercy Hospital & Medical Center-San Diego (GME)

VIEW ALL expand_more

Clinical Trials

A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma

Lead Researcher: Frank C Passero

The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

View Study Details

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment Naïve Patients With Mayo Stage IIIb AL Amyloidosis

Lead Researcher: Frank C Passero

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival and it is safe and well tolerated in patients with stage IIIb AL amyloidosis.

View Study Details

Publications

Journal Articles

2023
Komisarof J, Forman J, Goldman B, Syposs C, Passero F, Garbade E. "A Rare Case of Renal Thrombotic Microangiopathy and Focal Segmental Glomerulosclerosis Secondary to Plasma Cell Leukemia." Case reports in hematology.. 2023 2023:7803704. Epub 2023 Feb 18.

3/22/2022
Alom MS, Grewal R, Passero FC, Goldman B, Choung HYG. "Light chain deposition disease masquerading as smoking-associated nodular glomerulosclerosis with deposits identified by electron microscopy only." CEN case reports.. 2022 Mar 22; Epub 2022 Mar 22.

2022
Komisarof J, Lipof J, DiTursi J, Chowdhry A, Grace Choung HY, Burack WR, Constine L, Passero F. "An Unusual Case of Multiple Myeloma with Light-Chain Cast Nephropathy Secondary to a Very Large Plasmacytoma without Bone Marrow Involvement." Case reports in hematology.. 2022 2022:7531142. Epub 2022 Feb 21.

VIEW ALL PUBLICATIONS